Current Oncology Reports

, Volume 14, Issue 1, pp 35–43

Zoledronic Acid in the Treatment of Early-Stage Breast Cancer: Is There a Final Verdict?

Breast Cancer (KR Fox, Section Editor)

DOI: 10.1007/s11912-011-0209-5

Cite this article as:
Gnant, M. Curr Oncol Rep (2012) 14: 35. doi:10.1007/s11912-011-0209-5

Abstract

Breast cancer, which preferentially metastasizes to bone, is the most common malignancy among women worldwide and is a leading cause of death. Clinical data from large, phase 3 trials (ie, ABCSG-12, ZO-FAST, and AZURE) demonstrate significantly improved disease-free survival with zoledronic acid in some patient populations with early breast cancer. Although the interim results from the AZURE trial did not show a disease-free survival benefit with zoledronic acid in the overall patient population, subset analyses showed that zoledronic acid significantly improved disease-free survival in women with established postmenopausal status at baseline. Similarly, subset analyses of the ABCSG-12 trial showed greater benefits from zoledronic acid in patients over 40 years of age who theoretically would have achieved more complete ovarian suppression. Together, these data support a potential role for zoledronic acid beyond bone health in breast cancer and suggest that the endocrine environment may influence the anticancer potential of zoledronic acid.

Keywords

Anticancer Bisphosphonate Breast cancer Zoledronic acid 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Surgery, Comprehensive Cancer CenterMedical University of ViennaViennaAustria

Personalised recommendations